Center for Stem Cell Research (A Unit of inStem, Bengaluru, India), Christian Medical College, Vellore, Tamil Nadu, 632002, India.
Department of Biotechnology, Thiruvalluvar University, Vellore, Tamil Nadu, 632115, India.
Sci Rep. 2022 Aug 18;12(1):14033. doi: 10.1038/s41598-022-13783-0.
Numerous genes exert multifaceted roles in hematopoiesis. Therefore, we generated novel lineage-specific RNA interference (RNAi) lentiviral vectors, H23B-Ery-Lin-shRNA and H234B-Ery-Lin-shRNA, to probe the functions of these genes in erythroid cells without affecting other hematopoietic lineages. The lineage specificity of these vectors was confirmed by transducing multiple hematopoietic cells to express a fluorescent protein. Unlike the previously reported erythroid lineage RNAi vector, our vectors were designed for cloning the short hairpin RNAs (shRNAs) for any gene, and they also provide superior knockdown of the target gene expression with a single shRNA integration per cell. High-level lineage-specific downregulation of BCL11A and ZBTB7A, two well-characterized transcriptional repressors of HBG in adult erythroid cells, was achieved with substantial induction of fetal hemoglobin with a single-copy lentiviral vector integration. Transduction of primary healthy donor CD34 cells with these vectors resulted in >80% reduction in the target protein levels and up to 40% elevation in the γ-chain levels in the differentiated erythroid cells. Xenotransplantation of the human CD34 cells transduced with H23B-Ery-Lin-shBCL11A LV in immunocompromised mice showed ~ 60% reduction in BCL11A protein expression with ~ 40% elevation of γ-chain levels in the erythroid cells derived from the transduced CD34 cells. Overall, the novel erythroid lineage-specific lentiviral RNAi vectors described in this study provide a high-level knockdown of target gene expression in the erythroid cells, making them suitable for their use in gene therapy for hemoglobinopathies. Additionally, the design of these vectors also makes them ideal for high-throughput RNAi screening for studying normal and pathological erythropoiesis.
众多基因在造血过程中发挥多方面的作用。因此,我们生成了新型的谱系特异性 RNA 干扰 (RNAi) 慢病毒载体,H23B-Ery-Lin-shRNA 和 H234B-Ery-Lin-shRNA,以在不影响其他造血谱系的情况下探测这些基因在红细胞中的功能。这些载体的谱系特异性通过转导多种造血细胞表达荧光蛋白来确认。与之前报道的红细胞谱系 RNAi 载体不同,我们的载体设计用于克隆任何基因的短发夹 RNA (shRNA),并且它们还通过每个细胞整合一个 shRNA 提供对靶基因表达的优越敲低。用单拷贝慢病毒载体整合实现了对 BCL11A 和 ZBTB7A 的高水平谱系特异性下调,BCL11A 和 ZBTB7A 是成年红细胞中 HBG 的两个经过充分表征的转录抑制剂,同时伴随着胎儿血红蛋白的大量诱导。用这些载体转导原代健康供体 CD34 细胞导致靶蛋白水平降低>80%,分化的红细胞中 γ 链水平升高高达 40%。将用 H23B-Ery-Lin-shBCL11A LV 转导的人 CD34 细胞移植到免疫缺陷小鼠中,在源自转导的 CD34 细胞的红细胞中观察到 BCL11A 蛋白表达降低约 60%,γ 链水平升高约 40%。总体而言,本研究中描述的新型红细胞谱系特异性慢病毒 RNAi 载体在红细胞中提供了靶基因表达的高水平敲低,使其适合用于血红蛋白病的基因治疗。此外,这些载体的设计也使其成为研究正常和病理红细胞生成的高通量 RNAi 筛选的理想选择。